ovarian neoplasms/phosphatase

Povezava se shrani v odložišče

Izberite vrsto razvrščanja

10 rezultatov

Sub-type Specific Genomic Mutations in sBOTs

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

Introduction Borderline Ovarian Tumors (BOTs) behave indolently in the vast majority of cases and the prognosis is usually favorable. There is more evidence that two subtypes of BOTs represent a higher risk of recurrence or even progression to an invasive ovarian cancer. In case of a presentation

Anti—PD-L1 and SAbR for Ovarian Cancer

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

Screening/Baseline Procedures Assessments performed exclusively to determine eligibility for this study will be done only after obtaining informed consent. Assessments performed for clinical indications (not exclusively to determine study eligibility) may be used for baseline values even if the

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

PRIMARY OBJECTIVES: I. To evaluate the anti-tumor activity of cabozantinib (XL184) (cabozantinib-s-malate) in women with persistent or recurrent clear cell ovarian cancer, based on the proportion of patients who survive progression-free for at least 6 months and the proportion who have objective

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose and recommended phase 2 dose (MTD/RP2D) of daily oral MLN0128 (TORC1/2 inhibitor INK128) when administered with bevacizumab in patients with advanced solid tumors including recurrent glioblastoma (GBM). II. To evaluate the overall safety

Dual PETOvac - Dual Time PET/CT in the Preoperative Assessment of Ovarian Cancer

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

The use of PET/CT in ovarian cancer has not been well-established. The diagnosis usually includes physical examination (incl. pelvic examination), blood test incl. CA-125 and transvaginal ultrasound. Furthermore imaging includes CT of thorax/abdomen and/or MR of pelvic. Ninety per cent of the

Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

OUTLINE: This is a phase I/II multi-center study. Phase I: All patients will receive a fixed dose of pegylated liposomal doxorubicin (Doxil) of 40 mg/m2 administered IV every 28 days. The dose of BIBF 1120 will be escalated in successive cohorts of patients. A maximum of 12 cycles of combined

Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

PRIMARY OBJECTIVES: I. To assess the activity of the study regimen as measured by the proportion of patients who are alive and progression-free for at least 12 months after study entry in patients with newly diagnosed stage III or IV clear cell ovarian cancer in the following populations: patients

Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

OBJECTIVES: Primary - To determine the 90-day clinical benefit (defined as the sum of complete responses, partial responses, and stable disease) in patients with recurrent ovarian epithelial cancer treated with single agent fulvestrant. Secondary - To establish the time to termination of treatment

Bone Health in Gynecologic Cancers-does FOSAVANCE Help?

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

Objectives: 1. To evaluate the impact of bisphosphonates on bone mineral density (BMD=primary endpoint) in women with gynecologic malignancies undergoing chemotherapy. 2. To determine if bone loss in women with gynecologic malignancies undergoing chemotherapy is correlated with any of the

A Phase I Dose Finding Study of APO010 in Patients With Solid Tumors

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

Two-centre, open label, uncontrolled, dose-finding phase I study, to determine the safety and tolerability of APO010 administered by intravenous bolus injection once per week in patients with solid tumors, for whom therapy of proven efficacy does not exist or is no longer effective. The

Pridružite se naši
facebook strani

Herbal & Natural Medicine

Najbolj popolna baza zdravilnih zelišč, podprta z znanostjo

Deluje v 55 jezikih
Zeliščna zdravila, podprta z znanostjo
Prepoznavanje zelišč po sliki
Interaktivni GPS zemljevid - označite zelišča na lokaciji (kmalu)
Preberite znanstvene publikacije, povezane z vašim iskanjem
Iščite zdravilna zelišča po njihovih učinkih
Organizirajte svoje interese in bodite na tekočem z raziskavami novic, kliničnimi preskušanji in patenti

Vnesite simptom ali bolezen in preberite o zeliščih, ki bi lahko pomagala, vnesite zelišče in si oglejte bolezni in simptome, proti katerim se uporablja.
* Vse informacije temeljijo na objavljenih znanstvenih raziskavah